Evidence map›Paper›PMID 36297001›Full record

ArticleNutrients2022

BRD9 Inhibition by Natural Polyphenols Targets DNA Damage/Repair and Apoptosis in Human Colon Cancer Cells.

Sabeeta Kapoor, Elisabetta Damiani, Shan Wang, Ravirajan Dharmanand, Chakrapani Tripathi, Jorge Enrique Tovar Perez, Wan Mohaiza Dashwood, Praveen Rajendran, Roderick Hugh Dashwood

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Decreased Abundance of GenusGastro hep advances · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Sabeeta KapoorCenter for Epigenetics & Disease Prevention, Texas A&M Health, Houston, TX 77030, USA.
Elisabetta DamianiDepartment of Life and Environmental Sciences, Università Politecnica delle Marche, 60121 Ancona, Italy.
Shan WangStomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Hangzhou 310030, China.
Ravirajan DharmanandCenter for Infectious & Inflammatory Diseases, Texas A&M Health, Houston, TX 77030, USA.
Chakrapani TripathiCenter for Epigenetics & Disease Prevention, Texas A&M Health, Houston, TX 77030, USA.
Jorge Enrique Tovar PerezCenter for Epigenetics & Disease Prevention, Texas A&M Health, Houston, TX 77030, USA.
Wan Mohaiza DashwoodCenter for Epigenetics & Disease Prevention, Texas A&M Health, Houston, TX 77030, USA.
Praveen RajendranCenter for Epigenetics & Disease Prevention, Texas A&M Health, Houston, TX 77030, USA.ORCID 0000-0002-6221-7366
Roderick Hugh DashwoodCenter for Epigenetics & Disease Prevention, Texas A&M Health, Houston, TX 77030, USA.ORCID 0000-0003-0351-4034
Marche Polytechnic University · ITStomatology Hospital · CN

Funding

Dietary HDAC Inhibitors in Colon Cancer PreventionR01CA122959 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DASHWOOD, RODERICK H · 2008 to 2023
$4.3M
NCI NIH HHS CA122959NCI NIH HHS R01 CA122959
6 · The paper itself

Abstract

Epigenetic mechanisms play an important role in the etiology of colorectal cancer (CRC) and other malignancies due, in part, to deregulated bromodomain (BRD) functions. Inhibitors of the bromodomain and extraterminal (BET) family have entered into clinical trials as anticancer agents, and interest has grown in other acetyl 'reader' proteins as therapeutic targets, including non-BET member bromodomain-containing protein 9 (BRD9). We report here that overexpression of BRD9 is associated with poor prognosis in CRC patients, and that siRNA-mediated knockdown of BRD9 decreased cell viability and activated apoptosis in human colon cancer cells, coincident with increased DNA damage. Seeking natural compounds as BRD9 antagonists, molecular docking in silico identified several polyphenols such as Epigallocatechin-3-gallate (EGCG), Equol, Quercetin, and Aspalathin, with favorable binding energies, supported by BROMOscan

Indexed as

Antineoplastic AgentsColonic NeoplasmsApoptosisBromodomain Containing ProteinsDNA DamageEquolHumansMolecular Docking SimulationPolyphenolsQuercetinRNA, Small InterferingTranscription FactorsAntineoplastic AgentsBRD9 protein, humanBromodomain Containing ProteinsEquolPolyphenolsQuercetinRNA, Small InterferingTranscription Factorsapoptosisbromodomain inhibitioncolorectal cancermolecular docking

Identifiers

PMID36297001
PMCPMC9610492
OpenAlexW4306399132

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.